WEBULL

Drugs Made In America Acquisition amends Power Analytics merger terms to add founder share forfeiture, earnout provisions

PUBT · 2d ago
Drugs Made In America Acquisition amends Power Analytics merger terms to add founder share forfeiture, earnout provisions
  • Drugs Made In America Acquisition updated its merger deal with Power Analytics Global, which would combine the firms into a Nasdaq-listed company.
  • Amendment No. 3 requires the former sponsor to forfeit at least 50% of founder shares, with the rest subject to $12.5 and $15 earnouts.
  • It also calls for surrender of 430,000 private placement rights, cancellation of 45,092 ordinary shares, and added lock-ups for other founder holders.
  • The company must launch a tender or exchange offer for public rights at $0.25-$0.35 per right, funded outside the trust account.
  • Minimum cash was reset to a $30 million target and $15 million floor, with talks opened on adding a third target by Sept. 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-079678), on July 20, 2026, and is solely responsible for the information contained therein.